Identification and functional characterization of urinary protein biomarkers for RA
Authors' conclusion
IGLV3-1 is a novel urinary protein biomarker that reflects RA disease activity and predicts clinical outcomes.
Study context
- Population
- RA patients and healthy controls (HCs); two RA cohorts (cross-sectional and longitudinal) for population-based analysescohorts n = 301 and n = 214
- Comparison
- RA patients vs HCs; IGLV3-1 levels vs disease activity
- Outcome
- Urinary protein biomarkers of RA disease activity
Methodological detailsmulti-phase, proteomic discovery, ELISA validation in two independent cohorts, cross-sectional and longitudinal cohorts
- Multi-phase
- Proteomic discovery
- ELISA validation in two independent cohorts
- Cross-sectional and longitudinal cohorts
Main finding
As reported in the abstract
- Differentially expressed proteins (DEPs) identified between RA and HCs, enriched in immune-related pathways
- 209
- IGLV3-1 diagnostic potential (AUC), validated in two independent cohorts
- AUC = 0.99
- IGLV3-1 association with VAS (β, 95% CI 0.264-1.875)
- β = 1.070
- IGLV3-1 association with DAS28 (β, 95% CI 0.029-1.315)
- β = 0.672
- IGLV3-1 and likelihood of VAS pain improvement (OR, 95% CI 0.047-0.746)
- OR = 0.188
Original publication
Identification and functional characterization of urinary protein biomarkers for RA. Rheumatology (Oxford). Published 20 April 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →